Prostate Cell News Volume 10.41 | Nov 01 2019

TOP STORY

Immunogenicity of Prostate Cancer Is Augmented by BET Bromodomain Inhibition

Researchers characterized the effects of BET bromodomain inhibition using JQ1 on PD-L1 and HLA-BC expression in two human prostate cell lines, DU145 and PC3. RNA-Seq was performed to assess changes on a genome-wide level. [J Immunother Cancer] Full Article

(Ranked by impact factor of the journal)

Phospholipase D2 in Prostate Cancer: Protein Expression Changes with Gleason Score

Phospholipase D2 (PLD2) expression was analyzed by immunohistochemistry and western blotting. The effects of PLD2 inhibition on prostate cancer cell viability and cell motility were measured using MTS, colony forming and wound-healing assays. [Br J Cancer] Abstract

The Comprehensive Role of E-Cadherin in Maintaining Prostatic Epithelial Integrity during Oncogenic Transformation and Tumor Progression.

Scientists investigated the effect of E-cadherin loss in prostatic epithelium using newly developed genetically engineered mouse models. Deletion of E-cadherin in prostatic luminal epithelial cells with modified probasin promoter driven Cre induced the development of mouse prostatic intraepithelial neoplasia. [PLoS Genet] Full Article

Single-Nucleotide Polymorphism rs13426236 Contributes to an Increased Prostate Cancer Risk via Regulating MLPH Splicing Variant 4

Researchers performed an allele-specific reporter assay to determine if single-nucleotide polymorphism containing sequences functioned as an active enhancer. Compared to allele A, allele G showed significantly higher luciferase activity on the promoter of the splicing transcript V4 but not on the promoter of transcript V1 in two prostate cancer cell lines. [Mol Carcinog] Abstract

PEG-PLA Nanoparticles Decorated with Small-Molecule PSMA Ligand for Targeted Delivery of Galbanic Acid and Docetaxel to Prostate Cancer Cells

The authors reported a novel targeted self-assembled based on PEG-PLA nanoparticles containing galbanic acid and docetaxel, which was targeted using ((S)-2-(3-((S)-5-amino-1-carboxypentyl) ureido) pentanedioic acid, a small molecule inhibitor targeting prostate-specific membrane antigen, in a prostate cancer cell line. [J Cell Physiol] Abstract

Low Intensity Focused Ultrasound (LOFU)-Mediated Acoustic Immune Priming and Ablative Radiation Therapy for In Situ Tumor Vaccines

Investigators demonstrated that LOFU significantly induced expression and cell surface localization of heat shock proteins in murine breast and prostate adenocarcinoma cancer cell lines. [Sci Rep] Full Article

Docetaxel/Cabazitaxel and Fatty Acid Binding Protein 5 Inhibitors Produce Synergistic Inhibition of Prostate Cancer Growth

PC3, DU-145, and 22Rv1 prostate cancer cells were incubated with fatty acid-binding protein 5 inhibitors Stony Brook fatty acid-binding protein inhibitor 102 (SBFI-102) or SBFI-103 in the presence or absence of docetaxel or cabazitaxel, and cytotoxicity was evaluated using the 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyl tetrazolium bromide assay. [Prostate] Abstract

Analysis of Transcriptome, Selected Intracellular Signaling Pathways, Proliferation and Apoptosis of LNCaP Cells Exposed to High Leptin Concentrations

Investigators performed studies on the effects of high LEP concentration on gene expression profile, change of selected signaling pathways, proliferation and apoptosis of LNCaP cells. The real-time cell analyzer revealed inhibitory effect of LEP on cell proliferation, but lower LEP concentrations did not affect cell division. [Int J Mol Sci] Full Article

The Molecular Effects of Sulforaphane and Capsaicin on Metabolism upon Androgen and Tip60 Activation of Androgen Receptor

The authors evaluated the effect of androgen and Tip60 stimulus in androgen receptor pathway activation and HIF-1α stabilization, in terms of proliferation and cell metabolism in androgen-sensitive LNCaP cells. [Int J Mol Sci] Abstract

Inactivation of the Wnt/β-Catenin Signaling Pathway Underlies Inhibitory Role of MicroRNA-129-5p in Epithelial-Mesenchymal Transition and Angiogenesis of Prostate Cancer by Targeting ZIC2

To understand the role of microRNA-129-5p and ZIC2 in prostate cancer, DU145 cells were transfected with mimic or inhibitor of microRNA-129-5p, or si-ZIC2 and the expression of Wnt, β-catenin, E-cadherin, vimentin, N-cadherin, vascular endothelial growth factor, and CD31, as well as the extent of β-catenin phosphorylation was determined. [Cancer Cell Int] Full Article

Subscribe to one of our other 19 science newsletters such as Mammary Cell News & ESC & iPSC News.

Beyond the Biomarker Role: Prostate-Specific Antigen (PSA) in the Prostate Cancer Microenvironment

Scientists summarize the current standing of prostate-specific antigen (PSA) in prostate cancer progression as well as its utility in prostate cancer therapeutic approaches with an emphasis on the role of PSA in the tumor microenvironment. [Cancer Metastasis Rev] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

NCI Awards UCLA Prostate Cancer Program with Research of Excellence Grant

The prostate cancer program at the UCLA Jonsson Comprehensive Cancer Center and UCLA Health has been awarded an $8.7 million Specialized Program of Research Excellence, or SPORE, grant from the National Cancer Institute. [UCLA Health] Press Release

Dendreon Completes Enrollment of Phase III ProVent Clinical Trial Evaluating Sipuleucel-T in Men on Active Surveillance

Dendreon Pharmaceuticals announced early completion of patient enrollment of its Phase III ProVent clinical trial. More than 450 subjects were randomized in the large-scale clinical trial, which is evaluating the effectiveness of sipuleucel-T (PROVENGE^®) in reducing disease progression in men with early-stage prostate cancer on active surveillance. [Dendreon Pharmaceuticals (Business Wire, Inc.)] Press Release

Trump Nominates MD Anderson’s Stephen Hahn to Lead FDA

President Trump announced his intent to nominate Dr. Stephen Hahn to lead the FDA. Dr. Stephen Hahn is the chief medical executive at MD Anderson Cancer Center in Houston. While he is an accomplished physician and researcher, he has never worked in government, leaving his potential FDA agenda a mystery. [STAT News] Editorial

Swiss Authorities Probe Boehringer Ingelheim and Other Companies for Antitrust Practices

A Swiss government agency that last month opened an antitrust investigation into several drug makers and distributors has now disclosed the names of nearly a dozen companies that may have fixed the market for an ingredient used to make a treatment for stomach pain. [STAT News] Editorial

NEW Molecular Machines: From Biophysics to Physiology to Disease
July 12-17, 2020
West Dover, Vermont, United States

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Position – Identification of RNA Risk Elements in Cancer Biology (University of Maryland Eastern Shore)

NEW Clinical Research Scientist – Investigational Cancer Therapeutics (MD Anderson Cancer Center)

NEW Tenure-Track Faculty Scientist Position – Radiation Oncology (New York University)

Postdoctoral Studentship – Genomics of Hereditary Prostate Cancer (University of Manchester)

Postdoctoral Researcher – Prostate Tumor Microenvironment (NorthShore University Health System)

Postdoctoral Researcher – Prostate Cancer (University of California, San Francisco)

Postdoctoral Scholar – Hormone Therapy Resistance in Prostate Cancer (Duke University Medical Center)

Assistant Professor – Biology of Genitourinary Cancers (University of Chicago)

Postdoctoral Fellowship – Prostate Cancer (Weill Cornell Medicine)

Postdoctoral Fellowship – Molecular Mechanisms of Androgen Synthesis (Cleveland Clinic)

Postdoctoral Associate – Prostate and Breast Cancer (Baylor College of Medicine)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.